Eutilex Co.,Ltd. Logo

Eutilex Co.,Ltd.

Develops immunotherapeutics for cancers and autoimmune diseases via T-cell/antibody tech.

263050 | KO

Overview

Corporate Details

ISIN(s):
KR7263050007
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시

Description

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-08-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.0 KB
2023-08-07 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.9 KB
2023-08-07 00:00
[기재정정]전환사채(해외전환사채포함)발행후만기전사채취득
Korean 13.5 KB
2023-07-03 00:00
투자판단관련주요경영사항(임상시험계획변경승인)(EU103(항VSIG4 항체치료제) 고형암 대상 제1상 임상시험계획서(IND) 변경승인))
Korean 14.6 KB
2023-06-16 00:00
기업설명회(IR)개최
Korean 7.5 KB
2023-05-23 00:00
투자판단관련주요경영사항(임상시험계획변경승인신청)(EU103(항VSIG4 항체치료제) 고형엄 대상 제1상 임상시험계획서(IND) 변경승인신청)
Korean 14.4 KB
2023-05-15 00:00
분기보고서 (2023.03)
Korean 1.3 MB
2023-05-10 00:00
기타경영사항(자율공시)(돌연변이 EGFR 타겟의 키메라 항원 수용체 국내 특허권 취득)
Korean 6.3 KB
2023-05-10 00:00
기타경영사항(자율공시)(돌연변이 EGFR 및 EphA2 동시 타겟하는 키메라 항원 수용체 국내 특허권 취득)
Korean 6.7 KB
2023-04-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2023-04-06 00:00
[기재정정]기업설명회(IR)개최
Korean 13.0 KB
2023-03-31 00:00
정기주주총회결과
Korean 29.7 KB
2023-03-31 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 8.4 KB
2023-03-31 00:00
대표이사변경
Korean 12.4 KB
2023-03-31 00:00
[기재정정]사업보고서 (2022.12)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eutilex Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.